# Study Evaluating Safety of BT01001 Ophthalmic Solution

> **NCT07313722** · PHASE1 · RECRUITING · sponsor: **Beyang Therapeutics Co., Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BT01001 5 mg/ml（0.5%）
- **DRUG:** BT01001 10 mg/ml（1.0%）
- **DRUG:** BT01001 15 mg/ml（1.5%）
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07313722
- **Lead sponsor:** Beyang Therapeutics Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-17
- **Primary completion:** 2026-02
- **Final completion:** 2026-04
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07313722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07313722, "Study Evaluating Safety of BT01001 Ophthalmic Solution". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07313722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*